WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018083122) HUMAN FCRN BINDING ANTIBODY FOR USE IN TREATMENT OF ANTIBODY MEDIATED DISEASE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/083122 International Application No.: PCT/EP2017/077966
Publication Date: 11.05.2018 International Filing Date: 01.11.2017
IPC:
A61K 38/17 (2006.01) ,A61K 9/00 (2006.01) ,A61K 47/42 (2017.01) ,C07K 16/28 (2006.01) ,A61P 37/06 (2006.01) ,A61K 39/00 (2006.01)
Applicants: ARGENX BVBA[BE/BE]; Industriepark Zwijnaarde 7 Building C 9052 Zwijnaarde, BE
Inventors: ULRICHTS, Peter; BE
DREIER, Torsten; BE
DE HAARD, Johannes Joseph Wilhelmus; BE
Agent: BOULT WADE TENNANT; Verulam Gardens 70 Gray's Inn Road London Greater London WC1X 8BT, GB
Priority Data:
1618424.401.11.2016GB
Title (EN) HUMAN FCRN BINDING ANTIBODY FOR USE IN TREATMENT OF ANTIBODY MEDIATED DISEASE
(FR) ANTICORPS DE LIAISON AU FCRN HUMAIN DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT D'UNE MALADIE MÉDIÉE PAR DES ANTICORPS
Abstract:
(EN) A treatment regimen is disclosed for the treatment of human subjects afflicted with antibody mediated disease. The regimen comprises administering to the human subject an antibody molecule that binds to the human FcRn receptor with at least one of its CDRs and with a binding affinity at pH=6 of at least 10 nM. The regimen comprises administering a loading dose of at least 20 nM/Kg, and at least one maintenance dose of at least 10 nM/Kg.
(FR) L'invention concerne un régime de traitement pour le traitement de sujets humains atteints d'une maladie médiée par des anticorps. Le régime comprend l'administration au sujet humain d'une molécule d'anticorps qui se lie au récepteur FcRn humain avec au moins l'un de ses CDR et avec une affinité de liaison d'au moins 10 Nm à un pH = 6. Le régime comprend l'administration d'une dose de charge d'au moins 20 nM/Kg, et au moins une dose de maintien d'au moins 10 nM/Kg.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)